Bank of America Corp DE Sells 61,769 Shares of Insulet Corporation $PODD

Key Points

• Bank of America reduced its Insulet stake by 13.5%, selling 61,769 shares and retaining 396,040 shares valued at approximately $83.1 million.
• Other major institutions increased their positions, including Arrowstreet Capital, which raised its stake by 462.7%, while Norges Bank established a new position.
• Insulet reported strong quarterly results, with revenue up 23.5% year over year and EPS exceeding estimates, but weaker Type 2 diabetes customer retention led to reduced 2026 guidance and analyst price-target cuts.

Bank of America Corp DE cut its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 13.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 396,040 shares of the medical instruments supplier's stock after selling 61,769 shares during the quarter. Bank of America Corp DE owned approximately 0.57% of Insulet worth $83,105,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. State Street Corp grew its stake in Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier's stock worth $896,916,000 after purchasing an additional 65,317 shares in the last quarter. Geode Capital Management LLC increased its holdings in Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier's stock worth $568,274,000 after purchasing an additional 41,019 shares during the period. Invesco Ltd. increased its holdings in Insulet by 10.5% during the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier's stock worth $420,835,000 after purchasing an additional 141,167 shares during the period. Arrowstreet Capital Limited Partnership raised its position in Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock valued at $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Finally, Norges Bank bought a new stake in Insulet during the 4th quarter valued at $300,794,000.

Key Stories Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported strong second-quarter results, with revenue of $801.7 million, up 23.5% year over year, and adjusted EPS of $1.66 versus the $1.47 consensus estimate. The results indicate continued demand for the Omnipod platform despite emerging retention issues. Insulet Corporation Q2 2026 Earnings Call Summary
• Neutral Sentiment: Several law firms are seeking lead plaintiffs for a federal securities class action covering investors who purchased PODD shares between February 21, 2025, and May 26, 2026. The lead-plaintiff deadline is August 31, 2026; the allegations have not been proven. Pomerantz class-action announcement
• Negative Sentiment: Insulet reduced its 2026 revenue outlook after identifying weaker-than-expected retention among Type 2 diabetes users. Investors are concerned that the issue could temper Omnipod adoption and second-half growth, despite management maintaining that the broader growth opportunity remains intact. Insulet cuts 2026 revenue outlook
• Negative Sentiment: Analysts sharply cut their valuations following the guidance reduction. TD Cowen lowered its price target to $144 with a hold rating, UBS reduced its target to $150 with a neutral rating, JPMorgan cut its target to $152, and Leerink downgraded PODD to market perform. Benchmark and Stifel retained buy ratings but also lowered their targets. Analysts slash Insulet forecasts
• Negative Sentiment: Investor concerns also include two recent Omnipod recalls or voluntary medical-device corrections, which have raised questions about manufacturing quality, potential regulatory scrutiny and reputational damage. The newly filed lawsuit alleges securities-law violations related to these issues and the company’s disclosures. PODD shareholder alert

Insider Buying and Selling

In other news, Director Timothy C. Stonesifer bought 2,790 shares of the firm's stock in a transaction that occurred on Wednesday, June 3rd. The stock was bought at an average price of $143.51 per share, with a total value of $400,392.90. Following the completion of the transaction, the director directly owned 9,041 shares of the company's stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.36% of the stock is owned by insiders.

Analyst Ratings Changes

PODD has been the topic of a number of recent research reports. Raymond James Financial reissued an "outperform" rating and set a $180.00 price target on shares of Insulet in a research report on Thursday. Sanford C. Bernstein decreased their price objective on Insulet from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Thursday. Piper Sandler lowered their price objective on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Jefferies Financial Group lowered their price objective on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Finally, Oppenheimer downgraded shares of Insulet from an "outperform" rating to a "market perform" rating in a research report on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Insulet currently has an average rating of "Hold" and a consensus price target of $195.40.

Insulet Stock Performance

Shares of Insulet stock opened at $141.17 on Friday. The company has a market capitalization of $9.79 billion, a PE ratio of 26.39, a P/E/G ratio of 1.04 and a beta of 1.10. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.81 and a current ratio of 2.48. The company has a 50-day simple moving average of $155.42 and a two-hundred day simple moving average of $193.60. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts' consensus estimates of $1.47 by $0.19. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The business had revenue of $801.70 million for the quarter, compared to analysts' expectations of $787.39 million. During the same period last year, the business earned $1.17 EPS. The company's revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Research analysts expect that Insulet Corporation will post 6.51 EPS for the current fiscal year.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source